Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07330843

Assessment and Evolution of Narrative Identity and Its Relationship to Subjective Multidimensional Well-being and Multidimensional Recovery in First Episode Psychosis

First episode psychosis (FEP) constitutes an important subgroup within psychotic disorders, as the acute impact of a disorder at the time of diagnosis may differ from its long-term impact over the following decades. Narrative is identified as a sense of personal agency, of belonging to a social group, metacognition, and well-being. Patients with schizophrenia have lower levels of agency and communion compared to HIV-positive participants. However, the themes of agency and communion and metacognition do not reflect all factors representing narrative identity. In order to measure well-being, it is also necessary to introduce a specific and multidimensional measure that will allow a more precise understanding of the phenomenon.

In FEP, a link has been demonstrated between the specificity of self-recollection and functional outcomes. Given that the transitional developmental stage between adolescence and adulthood is a key developmental window for narrative identity as well as psychotic disorders and that narrative identity is positively associated with mental health, this study will therefore focus on the acquisition of narrative identity in the FEP. It will investigate the extent to which narrative identity has an impact on multidimensional subjective well-being and whether it can predict multidimensional subjective well-being over time. The study investigators hypothesize that the levels of the various components of narrative identity would be lower in cases of FEP compared to patients with other "chronic" psychotic conditions and controls.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Psychosis Mental Disorder Mental Disorders Psychotic Disorders Schizophrenia Spectrum and Other Psychotic Disorders

Age range

16 year–30 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Nîmes

Nîmes, 30029, France

Location contact

Anissa Megzari

CONTACT

[email protected]

04.66.68.42.36

Aurélie Schandrin

SUB_INVESTIGATOR

Julie Jourdan

PRINCIPAL_INVESTIGATOR

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject who has given their free and informed consent.
  • Subject who has signed the consent form.
  • Subject who is a member of or beneficiary of a health insurance plan.

For the FEP group:

  • Patient treated in a psychiatric department (consultation or hospitalization) for a FEP defined by:
  • Presence of positive psychotic symptoms (delusions and/or hallucinations and/or conceptual disorganization) evolving for at least one week, either every day or at least 3 times a week for at least one hour per occasion
  • Never having taken neuroleptic treatment with an antipsychotic purpose (with the exception of antipsychotic treatment initiated for the current episode)
  • Disorder meeting DSM 5 criteria from the following list: delusional disorder, brief psychotic disorder lasting more than 7 days, schizophreniform disorder, schizophrenia, schizoaffective disorder, substance-induced psychotic disorder lasting more than 7 days, other specific or non-specific schizophrenia spectrum disorder or other psychotic disorder, bipolar disorder I or II with mood-congruent and mood-incongruent psychotic features, substance-induced bipolar disorder with mood-congruent and mood-incongruent psychotic features, major depressive disorder with mood-congruent and mood-incongruent psychotic features

For the "Chronic" group:

  • Patients diagnosed with a disorder meeting DSM-5 criteria for more than 18 months from the following list: delusional disorder, brief psychotic disorder lasting more than 7 days, schizophreniform disorder, schizophrenia, schizoaffective disorder, substance-induced psychotic disorder lasting more than 7 days, other specific or non-specific schizophrenia spectrum disorder or other psychotic disorder, bipolar I or II disorder with mood-congruent and mood-incongruent psychotic features, substance-induced bipolar disorder with mood-congruent and mood-incongruent psychotic features, major depressive disorder with mood-congruent and mood-incongruent psychotic features

Exclusion criteria

  • The subject is participating in category 1 RIPH or a clinical drug trial or clinical investigation study, or is in a period of exclusion determined by a previous study
  • The patient is unable to express consent
  • It is impossible to give the subject informed information
  • The patient is under safeguard of justice or state guardianship
  • Pregnant or breastfeeding subject.
  • Patient with a history of traumatic brain injury
  • Patient with moderate to severe mental retardation (IQ ≤ 55)

For the FEP group:

  • FEP related to a drug-induced psychotic disorder or due to another medical condition

For the "Control" group:

  • Patient with lifetime experience of FEP
  • Patient with a diagnosis of a disorder meeting DSM-5 criteria from the following list: delusional disorder, brief psychotic disorder lasting more than 7 days, schizophrenia-like disorder, schizophrenia, schizoaffective disorder, substance-induced psychotic disorder lasting more than 7 days, other specific or non-specific schizophrenia spectrum disorder or other psychotic disorder, bipolar I or II disorder with mood-congruent and mood-incongruent psychotic features, bipolar disorder with mood-congruent and mood-incongruent psychotic features substance-induced mood, major depressive disorder with psychotic features congruent and incongruent with mood

Treatment and study plan

Narrative identity task

Other

Participants will be asked to elaborate five personal narratives in response to the different types of questions: trauma, transgression, negative memory, self-definition, and turning point.

Primary outcomes

  1. Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

    Time frame: Baseline (Day 0)

    7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

  2. Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

    Time frame: Month 6

    7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

  3. Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

    Time frame: Month 12

    7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

  4. Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

    Time frame: Month 18

    7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

  5. Emotional valence according to the question: "When you think about this story in your life, how positive or negative is this story in your life?"

    Time frame: Month 24

    7-point scale ranging from -3 "Extremely negative" to 3 "Extremely positive"

  6. Emotional intensity according to the question: "When you think about this story in your life, how intense is this story in your life?"

    Time frame: Baseline (Day 0)

    7-point scale ranging from 1 "Not at all intense" to 7 "Extremely intense" -

  7. Emotional intensity according to the question: "When you think about this story in your life, how intense is this story in your life?"

    Time frame: Month 6

    7-point scale ranging from 1 "Not at all intense" to 7 "Extremely intense" -

  8. Emotional intensity according to the question: "When you think about this story in your life, how intense is this story in your life?"

    Time frame: Month 12

    7-point scale ranging from 1 "Not at all intense" to 7 "Extremely intense" -

  9. Emotional intensity according to the question: "When you think about this story in your life, how intense is this story in your life?"

    Time frame: Month 18

    7-point scale ranging from 1 "Not at all intense" to 7 "Extremely intense" -

  10. Emotional intensity according to the question: "When you think about this story in your life, how intense is this story in your life?"

    Time frame: Month 24

    7-point scale ranging from 1 "Not at all intense" to 7 "Extremely intense" -

  11. Emotional tone according to the question "When you think about this story in your life, is it generally negative, mixed, neutral, or positive?"

    Time frame: Baseline (day 0)

    4-point scale ranging from 0 "Negative" to 4 "Positive."

  12. Emotional tone according to the question "When you think about this story in your life, is it generally negative, mixed, neutral, or positive?"

    Time frame: Month 6

    4-point scale ranging from 0 "Negative" to 4 "Positive."

  13. Emotional tone according to the question "When you think about this story in your life, is it generally negative, mixed, neutral, or positive?"

    Time frame: Month 12

    4-point scale ranging from 0 "Negative" to 4 "Positive."

  14. Emotional tone according to the question "When you think about this story in your life, is it generally negative, mixed, neutral, or positive?"

    Time frame: Month 18

    4-point scale ranging from 0 "Negative" to 4 "Positive."

  15. Emotional tone according to the question "When you think about this story in your life, is it generally negative, mixed, neutral, or positive?"

    Time frame: Month 24

    4-point scale ranging from 0 "Negative" to 4 "Positive."

Secondary outcomes

  1. Narrative identity between groups

    Time frame: Baseline (Day 0)

    PERMA Profiler questionnaire; a 15-item scale in which higher scores indicate greater well-being

  2. Narrative identity between groups

    Time frame: Month 6

    PERMA Profiler questionnaire; a 15-item scale in which higher scores indicate greater well-being

  3. Narrative identity between groups

    Time frame: Month 12

    PERMA Profiler questionnaire; a 15-item scale in which higher scores indicate greater well-being

  4. Narrative identity between groups

    Time frame: Month 18

    PERMA Profiler questionnaire; a 15-item scale in which higher scores indicate greater well-being

  5. Narrative identity between groups

    Time frame: Month 24

    PERMA Profiler questionnaire; a 15-item scale in which higher scores indicate greater well-being

  6. General health-related quality of life between groups

    Time frame: Baseline (day 0)

    EQ5D-5L questionnaire comprising five items representing the five dimensions, and a visual analog scale ranging from 0 to 100 (100 referring to the "best possible health state"). The responses are then into a 5-digit number describing the patient's health state (e.g "11111" indicates the absence of problems).

  7. General health-related quality of life between groups

    Time frame: Month 6

    EQ5D-5L questionnaire comprising five items representing the five dimensions, and a visual analog scale ranging from 0 to 100 (100 referring to the "best possible health state"). The responses are then into a 5-digit number describing the patient's health state (e.g "11111" indicates the absence of problems).

  8. General health-related quality of life between groups

    Time frame: Month 12

    EQ5D-5L questionnaire comprising five items representing the five dimensions, and a visual analog scale ranging from 0 to 100 (100 referring to the "best possible health state"). The responses are then into a 5-digit number describing the patient's health state (e.g "11111" indicates the absence of problems).

  9. General health-related quality of life between groups

    Time frame: Month 18

    EQ5D-5L questionnaire comprising five items representing the five dimensions, and a visual analog scale ranging from 0 to 100 (100 referring to the "best possible health state"). The responses are then into a 5-digit number describing the patient's health state (e.g "11111" indicates the absence of problems).

  10. General health-related quality of life between groups

    Time frame: Month 24

    EQ5D-5L questionnaire comprising five items representing the five dimensions, and a visual analog scale ranging from 0 to 100 (100 referring to the "best possible health state"). The responses are then into a 5-digit number describing the patient's health state (e.g "11111" indicates the absence of problems).

  11. Health-related quality of life between groups

    Time frame: Baseline (day 0)

    WHOQOL-Brief: a 26-item questionnaire including one item on overall quality of life, one item assessing general health, and one item from each of the 24 facets of the WHOQOL-100. Four types of five-point response scales measure intensity (Not at all-Extremely), capacity (Not at all-Completely), frequency (Never-Always), and evaluation (Very dissatisfied/Very poor-Very satisfied/Very good).

  12. Health-related quality of life between groups

    Time frame: Month 6

    WHOQOL-Brief: a 26-item questionnaire including one item on overall quality of life, one item assessing general health, and one item from each of the 24 facets of the WHOQOL-100. Four types of five-point response scales measure intensity (Not at all-Extremely), capacity (Not at all-Completely), frequency (Never-Always), and evaluation (Very dissatisfied/Very poor-Very satisfied/Very good).

  13. Health-related quality of life between groups

    Time frame: Month 12

    WHOQOL-Brief: a 26-item questionnaire including one item on overall quality of life, one item assessing general health, and one item from each of the 24 facets of the WHOQOL-100. Four types of five-point response scales measure intensity (Not at all-Extremely), capacity (Not at all-Completely), frequency (Never-Always), and evaluation (Very dissatisfied/Very poor-Very satisfied/Very good).

  14. Health-related quality of life between groups

    Time frame: Month 18

    WHOQOL-Brief: a 26-item questionnaire including one item on overall quality of life, one item assessing general health, and one item from each of the 24 facets of the WHOQOL-100. Four types of five-point response scales measure intensity (Not at all-Extremely), capacity (Not at all-Completely), frequency (Never-Always), and evaluation (Very dissatisfied/Very poor-Very satisfied/Very good).

  15. Health-related quality of life between groups

    Time frame: Month 24

    WHOQOL-Brief: a 26-item questionnaire including one item on overall quality of life, one item assessing general health, and one item from each of the 24 facets of the WHOQOL-100. Four types of five-point response scales measure intensity (Not at all-Extremely), capacity (Not at all-Completely), frequency (Never-Always), and evaluation (Very dissatisfied/Very poor-Very satisfied/Very good).

  16. Anxiety and depression between groups

    Time frame: Baseline (Day 0)

    Hospital Anxiety and Depression Scale questionnaire where a higher score indicates greater distress

  17. Anxiety and depression between groups

    Time frame: Month 6

    Hospital Anxiety and Depression Scale questionnaire where a higher score indicates greater distress

  18. Anxiety and depression between groups

    Time frame: Month 12

    Hospital Anxiety and Depression Scale questionnaire where a higher score indicates greater distress

  19. Anxiety and depression between groups

    Time frame: Month 18

    Hospital Anxiety and Depression Scale questionnaire where a higher score indicates greater distress

  20. Anxiety and depression between groups

    Time frame: Month 24

    Hospital Anxiety and Depression Scale questionnaire where a higher score indicates greater distress

  21. Autobiographical memory between groups

    Time frame: Baseline (day 0)

    Thinking About Life Experiences scale (TALE-15): 17-item questionnaire consists of two general questions followed by 15 specific items related to the functions of autobiographical memory, each composed of 5 sub-items. Responses are rated on a 5-point Likert scale ranging from "Almost never" to "Very frequently."

  22. Autobiographical memory between groups

    Time frame: Month 6

    Thinking About Life Experiences scale (TALE-15): 17-item questionnaire consists of two general questions followed by 15 specific items related to the functions of autobiographical memory, each composed of 5 sub-items. Responses are rated on a 5-point Likert scale ranging from "Almost never" to "Very frequently."

  23. Autobiographical memory between groups

    Time frame: Month 12

    Thinking About Life Experiences scale (TALE-15): 17-item questionnaire consists of two general questions followed by 15 specific items related to the functions of autobiographical memory, each composed of 5 sub-items. Responses are rated on a 5-point Likert scale ranging from "Almost never" to "Very frequently."

  24. Autobiographical memory between groups

    Time frame: Month 18

    Thinking About Life Experiences scale (TALE-15): 17-item questionnaire consists of two general questions followed by 15 specific items related to the functions of autobiographical memory, each composed of 5 sub-items. Responses are rated on a 5-point Likert scale ranging from "Almost never" to "Very frequently."

  25. Autobiographical memory between groups

    Time frame: Month 24

    Thinking About Life Experiences scale (TALE-15): 17-item questionnaire consists of two general questions followed by 15 specific items related to the functions of autobiographical memory, each composed of 5 sub-items. Responses are rated on a 5-point Likert scale ranging from "Almost never" to "Very frequently."

  26. Personality type between groups

    Time frame: Baseline (day 0)

    Big Five Inventory (BFI-10): assessing the five major personality traits: extraversion, agreeableness, conscientiousness, emotional stability, and openness.

  27. Personality type between groups

    Time frame: Month 6

    Big Five Inventory (BFI-10): assessing the five major personality traits: extraversion, agreeableness, conscientiousness, emotional stability, and openness.

  28. Personality type between groups

    Time frame: Month 12

    Big Five Inventory (BFI-10): assessing the five major personality traits: extraversion, agreeableness, conscientiousness, emotional stability, and openness.

  29. Personality type between groups

    Time frame: Month 18

    Big Five Inventory (BFI-10): assessing the five major personality traits: extraversion, agreeableness, conscientiousness, emotional stability, and openness.

  30. Personality type between groups

    Time frame: Month 24

    Big Five Inventory (BFI-10): assessing the five major personality traits: extraversion, agreeableness, conscientiousness, emotional stability, and openness.

  31. Symptomatology of psychotic disorders in the FEP and chronic groups

    Time frame: Baseline (day 0)

    Positive and negative symptom scale (PANSS). 30 items measuring 5 subscales: positive, negative, disorganization, hostility, and anxiety. Each item is rated on a 7-point Likert scale ranging from 1 (absent) to 7 (extreme). The positive subscale ranges from 7 to 49, the negative subscale from 8 to 56, the hostility subscale from 6 to 46, the disorganization subscale from 5 to 35, and the anxiety subscale from 4 to 28. The total score ranges from 30 to 210.

  32. Symptomatology of psychotic disorders in the FEP and chronic groups

    Time frame: Month 6

    Positive and negative symptom scale (PANSS). 30 items measuring 5 subscales: positive, negative, disorganization, hostility, and anxiety. Each item is rated on a 7-point Likert scale ranging from 1 (absent) to 7 (extreme). The positive subscale ranges from 7 to 49, the negative subscale from 8 to 56, the hostility subscale from 6 to 46, the disorganization subscale from 5 to 35, and the anxiety subscale from 4 to 28. The total score ranges from 30 to 210.

  33. Symptomatology of psychotic disorders in the FEP and chronic groups

    Time frame: Month 12

    Positive and negative symptom scale (PANSS). 30 items measuring 5 subscales: positive, negative, disorganization, hostility, and anxiety. Each item is rated on a 7-point Likert scale ranging from 1 (absent) to 7 (extreme). The positive subscale ranges from 7 to 49, the negative subscale from 8 to 56, the hostility subscale from 6 to 46, the disorganization subscale from 5 to 35, and the anxiety subscale from 4 to 28. The total score ranges from 30 to 210.

  34. Symptomatology of psychotic disorders in the FEP and chronic groups

    Time frame: Month 18

    Positive and negative symptom scale (PANSS). 30 items measuring 5 subscales: positive, negative, disorganization, hostility, and anxiety. Each item is rated on a 7-point Likert scale ranging from 1 (absent) to 7 (extreme). The positive subscale ranges from 7 to 49, the negative subscale from 8 to 56, the hostility subscale from 6 to 46, the disorganization subscale from 5 to 35, and the anxiety subscale from 4 to 28. The total score ranges from 30 to 210.

  35. Symptomatology of psychotic disorders in the FEP and chronic groups

    Time frame: Month 24

    Positive and negative symptom scale (PANSS). 30 items measuring 5 subscales: positive, negative, disorganization, hostility, and anxiety. Each item is rated on a 7-point Likert scale ranging from 1 (absent) to 7 (extreme). The positive subscale ranges from 7 to 49, the negative subscale from 8 to 56, the hostility subscale from 6 to 46, the disorganization subscale from 5 to 35, and the anxiety subscale from 4 to 28. The total score ranges from 30 to 210.

  36. Overall functioning in the FEP and chronic groups

    Time frame: Baseline (day 0)

    Global Assessment of Functioning (GAF). This numerical scale (from 0 to 100) subjectively assesses functioning in social, occupational, and psychological domains. Lower scores represent lower levels of functioning

  37. Overall functioning in the FEP and chronic groups

    Time frame: Month 6

    Global Assessment of Functioning (GAF). This numerical scale (from 0 to 100) subjectively assesses functioning in social, occupational, and psychological domains. Lower scores represent lower levels of functioning

  38. Overall functioning in the FEP and chronic groups

    Time frame: Month 12

    Global Assessment of Functioning (GAF). This numerical scale (from 0 to 100) subjectively assesses functioning in social, occupational, and psychological domains. Lower scores represent lower levels of functioning

  39. Overall functioning in the FEP and chronic groups

    Time frame: Month 18

    Global Assessment of Functioning (GAF). This numerical scale (from 0 to 100) subjectively assesses functioning in social, occupational, and psychological domains. Lower scores represent lower levels of functioning

  40. Overall functioning in the FEP and chronic groups

    Time frame: Month 24

    Global Assessment of Functioning (GAF). This numerical scale (from 0 to 100) subjectively assesses functioning in social, occupational, and psychological domains. Lower scores represent lower levels of functioning

  41. Personal recovery in the FEP and chronic groups

    Time frame: Baseline (day 0)

    Stage of recovery instrument (STORI): a 50-item questionnaire that evaluates the five stages of personal recovery. Ten themes are assessed, each containing five items ranging from 0 "Not at all true" to 5 "Completely true," corresponding to the five stages of personal recovery. A score is calculated for each stage, ranging from 0 to 50

  42. Personal recovery in the FEP and chronic groups

    Time frame: Month 6

    Stage of recovery instrument (STORI): a 50-item questionnaire that evaluates the five stages of personal recovery. Ten themes are assessed, each containing five items ranging from 0 "Not at all true" to 5 "Completely true," corresponding to the five stages of personal recovery. A score is calculated for each stage, ranging from 0 to 50

  43. Personal recovery in the FEP and chronic groups

    Time frame: Month 12

    Stage of recovery instrument (STORI): a 50-item questionnaire that evaluates the five stages of personal recovery. Ten themes are assessed, each containing five items ranging from 0 "Not at all true" to 5 "Completely true," corresponding to the five stages of personal recovery. A score is calculated for each stage, ranging from 0 to 50

  44. Personal recovery in the FEP and chronic groups

    Time frame: Month 18

    Stage of recovery instrument (STORI): a 50-item questionnaire that evaluates the five stages of personal recovery. Ten themes are assessed, each containing five items ranging from 0 "Not at all true" to 5 "Completely true," corresponding to the five stages of personal recovery. A score is calculated for each stage, ranging from 0 to 50

  45. Personal recovery in the FEP and chronic groups

    Time frame: Month 24

    Stage of recovery instrument (STORI): a 50-item questionnaire that evaluates the five stages of personal recovery. Ten themes are assessed, each containing five items ranging from 0 "Not at all true" to 5 "Completely true," corresponding to the five stages of personal recovery. A score is calculated for each stage, ranging from 0 to 50

  46. Social and individual performance in the FEP and chronic groups

    Time frame: Baseline (day 0)

    Personal and social performance scale (PSP): measures four domains of social and individual functioning (socially useful activities, personal and social relationships, self-care, disruptive and aggressive behaviors) and provides a score between 1 and 100, divided into 10 equal intervals to assess the degree of difficulty. Higher scores correspond to better personal and social functioning, with scores of 91 to 100 indicating more than adequate functioning, while scores below 30 indicate such poor functioning that intensive supervision is required.

  47. Social and individual performance in the FEP and chronic groups

    Time frame: Month 6

    Personal and social performance scale (PSP): measures four domains of social and individual functioning (socially useful activities, personal and social relationships, self-care, disruptive and aggressive behaviors) and provides a score between 1 and 100, divided into 10 equal intervals to assess the degree of difficulty. Higher scores correspond to better personal and social functioning, with scores of 91 to 100 indicating more than adequate functioning, while scores below 30 indicate such poor functioning that intensive supervision is required.

  48. Social and individual performance in the FEP and chronic groups

    Time frame: Month 12

    Personal and social performance scale (PSP): measures four domains of social and individual functioning (socially useful activities, personal and social relationships, self-care, disruptive and aggressive behaviors) and provides a score between 1 and 100, divided into 10 equal intervals to assess the degree of difficulty. Higher scores correspond to better personal and social functioning, with scores of 91 to 100 indicating more than adequate functioning, while scores below 30 indicate such poor functioning that intensive supervision is required.

  49. Social and individual performance in the FEP and chronic groups

    Time frame: Month 18

    Personal and social performance scale (PSP): measures four domains of social and individual functioning (socially useful activities, personal and social relationships, self-care, disruptive and aggressive behaviors) and provides a score between 1 and 100, divided into 10 equal intervals to assess the degree of difficulty. Higher scores correspond to better personal and social functioning, with scores of 91 to 100 indicating more than adequate functioning, while scores below 30 indicate such poor functioning that intensive supervision is required.

  50. Social and individual performance in the FEP and chronic groups

    Time frame: Month 24

    Personal and social performance scale (PSP): measures four domains of social and individual functioning (socially useful activities, personal and social relationships, self-care, disruptive and aggressive behaviors) and provides a score between 1 and 100, divided into 10 equal intervals to assess the degree of difficulty. Higher scores correspond to better personal and social functioning, with scores of 91 to 100 indicating more than adequate functioning, while scores below 30 indicate such poor functioning that intensive supervision is required.

  51. Improvement of clinical state in the FEP and chronic groups

    Time frame: Baseline (day 0)

    Clinical global impression (CGI): a global observer-rated assessment tool that measures a patient's clinical condition before and after medical treatment. It consists of two measures: Severity, which measures the severity of the patient's clinical condition; and Improvement, which assesses the improvement in the patient's clinical condition since the start of treatment, both on a scale of 1 to 7.

  52. Improvement of clinical state in the FEP and chronic groups

    Time frame: Month 6

    Clinical global impression (CGI): a global observer-rated assessment tool that measures a patient's clinical condition before and after medical treatment. It consists of two measures: Severity, which measures the severity of the patient's clinical condition; and Improvement, which assesses the improvement in the patient's clinical condition since the start of treatment, both on a scale of 1 to 7.

  53. Improvement of clinical state in the FEP and chronic groups

    Time frame: Month 12

    Clinical global impression (CGI): a global observer-rated assessment tool that measures a patient's clinical condition before and after medical treatment. It consists of two measures: Severity, which measures the severity of the patient's clinical condition; and Improvement, which assesses the improvement in the patient's clinical condition since the start of treatment, both on a scale of 1 to 7.

  54. Improvement of clinical state in the FEP and chronic groups

    Time frame: Month 18

    Clinical global impression (CGI): a global observer-rated assessment tool that measures a patient's clinical condition before and after medical treatment. It consists of two measures: Severity, which measures the severity of the patient's clinical condition; and Improvement, which assesses the improvement in the patient's clinical condition since the start of treatment, both on a scale of 1 to 7.

  55. Improvement of clinical state in the FEP and chronic groups

    Time frame: Month 24

    Clinical global impression (CGI): a global observer-rated assessment tool that measures a patient's clinical condition before and after medical treatment. It consists of two measures: Severity, which measures the severity of the patient's clinical condition; and Improvement, which assesses the improvement in the patient's clinical condition since the start of treatment, both on a scale of 1 to 7.

  56. Awareness of the disorders in the FEP and chronic groups

    Time frame: Baseline (day 0)

    Birchwood insight scale (BIS); multidimensional assessment of awareness of illness (insight) and includes 8 questions (3-point Likert scale: "agree," "disagree," or "uncertain"). The overall score ranges from 0 to 12, with a score above 9 indicating good insight.

  57. Awareness of the disorders in the FEP and chronic groups

    Time frame: Month 6

    Birchwood insight scale (BIS); multidimensional assessment of awareness of illness (insight) and includes 8 questions (3-point Likert scale: "agree," "disagree," or "uncertain"). The overall score ranges from 0 to 12, with a score above 9 indicating good insight.

  58. Awareness of the disorders in the FEP and chronic groups

    Time frame: Month 12

    Birchwood insight scale (BIS); multidimensional assessment of awareness of illness (insight) and includes 8 questions (3-point Likert scale: "agree," "disagree," or "uncertain"). The overall score ranges from 0 to 12, with a score above 9 indicating good insight.

  59. Awareness of the disorders in the FEP and chronic groups

    Time frame: Month 18

    Birchwood insight scale (BIS); multidimensional assessment of awareness of illness (insight) and includes 8 questions (3-point Likert scale: "agree," "disagree," or "uncertain"). The overall score ranges from 0 to 12, with a score above 9 indicating good insight.

  60. Awareness of the disorders in the FEP and chronic groups

    Time frame: Month 24

    Birchwood insight scale (BIS); multidimensional assessment of awareness of illness (insight) and includes 8 questions (3-point Likert scale: "agree," "disagree," or "uncertain"). The overall score ranges from 0 to 12, with a score above 9 indicating good insight.

  61. Abstract verbal reasoning in the FEP and chronic groups

    Time frame: Baseline (day 0)

    Similarities section of the Wechsler Adult Intelligence Scale (WAIS): For 18 pairs of words, the participant subject must identify the qualitative relationship between the two words

  62. Abstract verbal reasoning in the FEP and chronic groups

    Time frame: Month 6

    Similarities section of the Wechsler Adult Intelligence Scale (WAIS): For 18 pairs of words, the participant subject must identify the qualitative relationship between the two words

  63. Abstract verbal reasoning in the FEP and chronic groups

    Time frame: Month 12

    Similarities section of the Wechsler Adult Intelligence Scale (WAIS): For 18 pairs of words, the participant subject must identify the qualitative relationship between the two words

  64. Abstract verbal reasoning in the FEP and chronic groups

    Time frame: Month 18

    Similarities section of the Wechsler Adult Intelligence Scale (WAIS): For 18 pairs of words, the participant subject must identify the qualitative relationship between the two words

  65. Abstract verbal reasoning in the FEP and chronic groups

    Time frame: Month 24

    Similarities section of the Wechsler Adult Intelligence Scale (WAIS): For 18 pairs of words, the participant subject must identify the qualitative relationship between the two words

  66. Non-verbal abstract problem solving in the FEP and chronic groups

    Time frame: Baseline (day 0)

    Matrix reasoning section of the Wechsler Adult Intelligence Scale (WAIS); in which participants must identify patterns in drawings

  67. Non-verbal abstract problem solving in the FEP and chronic groups

    Time frame: Month 6

    Matrix reasoning section of the Wechsler Adult Intelligence Scale (WAIS); in which participants must identify patterns in drawings

  68. Non-verbal abstract problem solving in the FEP and chronic groups

    Time frame: Month 12

    Matrix reasoning section of the Wechsler Adult Intelligence Scale (WAIS); in which participants must identify patterns in drawings

  69. Non-verbal abstract problem solving in the FEP and chronic groups

    Time frame: Month 18

    Matrix reasoning section of the Wechsler Adult Intelligence Scale (WAIS); in which participants must identify patterns in drawings

  70. Non-verbal abstract problem solving in the FEP and chronic groups

    Time frame: Month 24

    Matrix reasoning section of the Wechsler Adult Intelligence Scale (WAIS); in which participants must identify patterns in drawings

  71. Treatment adherence in the FEP and chronic groups

    Time frame: Baseline (day 0)

    Medication adherence rating scale (MARS): 10-item questionnaire concerning medication adherence during the past week assessing behaviors, attitudes, and experiences related to the treatment.

  72. Treatment adherence in the FEP and chronic groups

    Time frame: Month 6

    Medication adherence rating scale (MARS): 10-item questionnaire concerning medication adherence during the past week assessing behaviors, attitudes, and experiences related to the treatment.

  73. Treatment adherence in the FEP and chronic groups

    Time frame: Month 12

    Medication adherence rating scale (MARS): 10-item questionnaire concerning medication adherence during the past week assessing behaviors, attitudes, and experiences related to the treatment.

  74. Treatment adherence in the FEP and chronic groups

    Time frame: Month 18

    Medication adherence rating scale (MARS): 10-item questionnaire concerning medication adherence during the past week assessing behaviors, attitudes, and experiences related to the treatment.

  75. Treatment adherence in the FEP and chronic groups

    Time frame: Month 24

    Medication adherence rating scale (MARS): 10-item questionnaire concerning medication adherence during the past week assessing behaviors, attitudes, and experiences related to the treatment.

  76. Episodic memory between groups

    Time frame: Baseline (day 0)

    California Verbal Learning Test--Second Edition (CVLT): in this word list recall and recognition test, the examiner reads a list of 16 nouns aloud at one-second intervals in a fixed order over five learning trials. The participant is asked to recall as many words as possible in any order (free recall). If subjects "cluster" words from each category, they are presumably using semantic organization. Free recall is tested immediately (short-term recall) and again after 20 minutes (long-term recall).

  77. Episodic memory between groups

    Time frame: Month 6

    California Verbal Learning Test--Second Edition (CVLT): in this word list recall and recognition test, the examiner reads a list of 16 nouns aloud at one-second intervals in a fixed order over five learning trials. The participant is asked to recall as many words as possible in any order (free recall). If subjects "cluster" words from each category, they are presumably using semantic organization. Free recall is tested immediately (short-term recall) and again after 20 minutes (long-term recall).

  78. Episodic memory between groups

    Time frame: Month 12

    California Verbal Learning Test--Second Edition (CVLT): in this word list recall and recognition test, the examiner reads a list of 16 nouns aloud at one-second intervals in a fixed order over five learning trials. The participant is asked to recall as many words as possible in any order (free recall). If subjects "cluster" words from each category, they are presumably using semantic organization. Free recall is tested immediately (short-term recall) and again after 20 minutes (long-term recall).

  79. Episodic memory between groups

    Time frame: Month 18

    California Verbal Learning Test--Second Edition (CVLT): in this word list recall and recognition test, the examiner reads a list of 16 nouns aloud at one-second intervals in a fixed order over five learning trials. The participant is asked to recall as many words as possible in any order (free recall). If subjects "cluster" words from each category, they are presumably using semantic organization. Free recall is tested immediately (short-term recall) and again after 20 minutes (long-term recall).

  80. Episodic memory between groups

    Time frame: Month 24

    California Verbal Learning Test--Second Edition (CVLT): in this word list recall and recognition test, the examiner reads a list of 16 nouns aloud at one-second intervals in a fixed order over five learning trials. The participant is asked to recall as many words as possible in any order (free recall). If subjects "cluster" words from each category, they are presumably using semantic organization. Free recall is tested immediately (short-term recall) and again after 20 minutes (long-term recall).

Study contacts

Contact information is provided by the study sponsor or research team.

Julie Jourdan

CONTACT

[email protected]

04.66.68.34.26

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Official study title

Évaluation et évolution de l'identité Narrative et de Son Lien Avec le Bien-être Multidimensionnel Subjectif et le rétablissement Multidimensionnel Dans le Premier épisode Psychotique

Acronym: PEPID

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jan 9, 2026
Registry last updated
Jan 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.